UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
(
(Registrant’s telephone number,
including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 9, 2020, Corey N. Fishman notified Momenta Pharmaceuticals, Inc. (the “Company”) of his decision not to stand for re-election to the Company’s Board of Directors (the “Board”) at the Company’s annual meeting of stockholders. Mr. Fishman has served as a director since 2016 and currently serves as a member of the Audit Committee and Nominating and Corporate Governance Committee. Mr. Fishman’s decision not to seek re-election was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices and was due in part to Glass Lewis’ and certain stockholders’ guidelines regarding overboarding, as he has joined an additional public company board.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOMENTA PHARMACEUTICALS, INC. | ||
Date: April 10, 2020 | By: | /s/ Craig A. Wheeler |
Craig A. Wheeler President and Chief Executive Officer |
3
MX"DG,,34-Q_#A-S'HTY@DBEP'\&$W,?S3F"<*7 ?8K*0^WCF"4QT!MR'F-"!
MX:DG,-,9]44@)B2"YY[ 5&?@AD%,0(3BP:
Cover |
Apr. 09, 2020 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Apr. 09, 2020 |
Entity File Number | 000-50797 |
Entity Registrant Name | Momenta Pharmaceuticals, Inc. |
Entity Central Index Key | 0001235010 |
Entity Tax Identification Number | 04-3561634 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 301 Binney Street |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02142 |
City Area Code | 617 |
Local Phone Number | 491-9700 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.0001 par value per share |
Trading Symbol | MNTA |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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